Government Seeks Data on Rituxan Marketing
- Share via
From Bloomberg News
Genentech Inc. said it received a request for information from the U.S. attorney’s office about its promotion of the cancer drug Rituxan.
Genentech of South San Francisco received the subpoena as part of a civil and criminal investigation by the U.S. attorney in Philadelphia, Genentech said. A Genentech spokeswoman declined to comment on the reasons for the investigation.
Genentech shares rose 83 cents to $53.99 on the New York Stock Exchange before the subpoena was disclosed.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
